[{"id":"e3b4bad8-8656-47cc-998e-a5d2146657b6","acronym":"ALCHEMIST Screening","url":"https://clinicaltrials.gov/study/NCT02194738","created_at":"2021-01-18T10:15:39.910Z","updated_at":"2025-02-25T12:26:10.714Z","phase":"","brief_title":"Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)","source_id_and_acronym":"NCT02194738 - ALCHEMIST Screening","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1 • ALK • PIK3CA • PTEN • PD-1 • CTLA4","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement","tags":["EGFR • PD-L1 • ALK • PIK3CA • PTEN • PD-1 • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Lynparza (olaparib) • cisplatin • Xalkori (crizotinib) • erlotinib • carboplatin • gemcitabine • paclitaxel • docetaxel • Mektovi (binimetinib) • pemetrexed • sapanisertib (CB-228) • Zaltrap (ziv-aflibercept IV) • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • Pembroria (pembrolizumab biosimilar) • Pemfexy (pemetrexed) • liposomal gemcitabine (FF-10832)"],"overall_status":"Recruiting","enrollment":" Enrollment 8300","initiation":"Initiation: 09/26/2014","start_date":" 09/26/2014","primary_txt":" Primary completion: 09/28/2026","primary_completion_date":" 09/28/2026","study_txt":" Completion: 09/28/2026","study_completion_date":" 09/28/2026","last_update_posted":"2025-02-24"},{"id":"16a15023-befe-4ca0-9aaa-23efe0cc2225","acronym":"MK-7119-001","url":"https://clinicaltrials.gov/study/NCT04721977","created_at":"2021-01-25T15:53:18.932Z","updated_at":"2025-02-25T13:49:04.272Z","phase":"Phase 2","brief_title":"A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)","source_id_and_acronym":"NCT04721977 - MK-7119-001","lead_sponsor":"Pfizer","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • capecitabine • Tukysa (tucatinib) • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 04/08/2021","start_date":" 04/08/2021","primary_txt":" Primary completion: 07/17/2023","primary_completion_date":" 07/17/2023","study_txt":" Completion: 11/25/2025","study_completion_date":" 11/25/2025","last_update_posted":"2025-02-20"},{"id":"ea16c3dc-6884-43c3-8786-5858a4804bcc","acronym":"","url":"https://clinicaltrials.gov/study/NCT04024462","created_at":"2021-01-18T19:45:27.762Z","updated_at":"2025-02-25T12:27:15.491Z","phase":"Phase 3","brief_title":"A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer","source_id_and_acronym":"NCT04024462","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PIK3CA","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification • PIK3CA mutation • EGFR positive","tags":["PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification • PIK3CA mutation • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • docetaxel • tamoxifen • doxorubicin hydrochloride • cyclophosphamide • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 02/05/2020","start_date":" 02/05/2020","primary_txt":" Primary completion: 12/13/2021","primary_completion_date":" 12/13/2021","study_txt":" Completion: 11/11/2025","study_completion_date":" 11/11/2025","last_update_posted":"2024-12-20"},{"id":"edfdc24f-022c-4bdf-b95b-7542ea085b87","acronym":"ATEMPT 2.0","url":"https://clinicaltrials.gov/study/NCT04893109","created_at":"2021-05-19T15:52:52.041Z","updated_at":"2024-07-02T16:34:27.345Z","phase":"Phase 2","brief_title":"ATEMPT 2.0: Adjuvant T-DM1 vs TH","source_id_and_acronym":"NCT04893109 - ATEMPT 2.0","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • Kadcyla (ado-trastuzumab emtansine) • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk)"],"overall_status":"Recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 06/16/2021","start_date":" 06/16/2021","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2028","study_completion_date":" 05/01/2028","last_update_posted":"2024-06-11"},{"id":"ed815c0f-e035-457c-bdd2-620951dfd038","acronym":"","url":"https://clinicaltrials.gov/study/NCT06100874","created_at":"2023-10-25T19:14:19.283Z","updated_at":"2024-07-02T16:35:00.165Z","phase":"Phase 2","brief_title":"A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)","source_id_and_acronym":"NCT06100874","lead_sponsor":"Adrienne G. Waks","biomarkers":" HER-2","pipe":" | ","alterations":" PGR expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Trodelvy (sacituzumab govitecan-hziy) • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 11/20/2023","start_date":" 11/20/2023","primary_txt":" Primary completion: 11/30/2026","primary_completion_date":" 11/30/2026","study_txt":" Completion: 11/30/2027","study_completion_date":" 11/30/2027","last_update_posted":"2024-05-30"},{"id":"e534352f-a569-44ce-8b3f-0ef8e604d017","acronym":"PHERGAIN-2","url":"https://clinicaltrials.gov/study/NCT04733118","created_at":"2021-02-01T16:58:14.957Z","updated_at":"2025-02-25T12:27:54.966Z","phase":"Phase 2","brief_title":"Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer","source_id_and_acronym":"NCT04733118 - PHERGAIN-2","lead_sponsor":"MedSIR","biomarkers":" HER-2 • ER • PGR","pipe":"","alterations":" ","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 393","initiation":"Initiation: 08/05/2021","start_date":" 08/05/2021","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 03/01/2028","study_completion_date":" 03/01/2028","last_update_posted":"2024-03-13"},{"id":"df83f8b3-fce6-4513-b771-f6b292dad290","acronym":"","url":"https://clinicaltrials.gov/study/NCT05458674","created_at":"2022-07-14T13:54:27.368Z","updated_at":"2024-07-02T16:35:15.476Z","phase":"Phase 2","brief_title":"Tucatinib+Trastuzumab+Eribulin in HER2+ MBC","source_id_and_acronym":"NCT05458674","lead_sponsor":"Criterium, Inc.","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Halaven (eribulin mesylate) • Tukysa (tucatinib) • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 01/01/2024","start_date":" 01/01/2024","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2024-03-11"},{"id":"339a8951-c9c8-424d-9220-16cf89626ede","acronym":"ChangHER-SC","url":"https://clinicaltrials.gov/study/NCT01875367","created_at":"2021-01-18T08:24:28.179Z","updated_at":"2024-07-02T16:35:51.335Z","phase":"Phase 3","brief_title":"Phase III to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous in HER2+ Advanced Breast Cancer","source_id_and_acronym":"NCT01875367 - ChangHER-SC","lead_sponsor":"Spanish Breast Cancer Research Group","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 amplification • EGFR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin Hylecta (trastuzumab/hyaluronidase-oysk)"],"overall_status":"Completed","enrollment":" Enrollment 166","initiation":"Initiation: 09/18/2013","start_date":" 09/18/2013","primary_txt":" Primary completion: 11/30/2016","primary_completion_date":" 11/30/2016","study_txt":" Completion: 04/30/2018","study_completion_date":" 04/30/2018","last_update_posted":"2023-04-05"},{"id":"5c405c10-6bc1-4c4f-874c-ea23f47ea47a","acronym":"TRAIN-3","url":"https://clinicaltrials.gov/study/NCT03820063","created_at":"2021-01-18T18:52:21.606Z","updated_at":"2025-02-25T13:52:46.267Z","phase":"Phase 2","brief_title":"Image-guided De-escalation of Neo-adjuvant Chemotherapy in HER2-positive Breast Cancer: the TRAIN-3 Study","source_id_and_acronym":"NCT03820063 - TRAIN-3","lead_sponsor":"Borstkanker Onderzoek Groep","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • carboplatin • paclitaxel • Perjeta (pertuzumab) • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 462","initiation":"Initiation: 02/27/2019","start_date":" 02/27/2019","primary_txt":" Primary completion: 11/15/2022","primary_completion_date":" 11/15/2022","study_txt":" Completion: 05/01/2032","study_completion_date":" 05/01/2032","last_update_posted":"2023-02-22"},{"id":"dd0ebb9d-78f3-4a27-a09b-20c1b897898e","acronym":"BREASTIMMU02","url":"https://clinicaltrials.gov/study/NCT03571633","created_at":"2021-01-18T17:34:31.757Z","updated_at":"2024-07-02T16:35:57.881Z","phase":"Phase 2","brief_title":"Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer","source_id_and_acronym":"NCT03571633 - BREASTIMMU02","lead_sponsor":"Centre Leon Berard","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk) • Neulasta (pegfilgrastim)"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 08/06/2018","start_date":" 08/06/2018","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 04/01/2024","study_completion_date":" 04/01/2024","last_update_posted":"2023-01-10"},{"id":"e4c33f60-0a92-42ee-b93c-59a6b0260058","acronym":"","url":"https://clinicaltrials.gov/study/NCT04395508","created_at":"2021-01-18T21:12:43.952Z","updated_at":"2025-02-25T12:27:34.249Z","phase":"","brief_title":"An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic","source_id_and_acronym":"NCT04395508","lead_sponsor":"Genentech, Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 amplification • EGFR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk)"],"overall_status":"Approved for marketing","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2022-07-04"},{"id":"328298b3-31f0-4ce5-a8d9-bf0e09b91e2d","acronym":"SafeHER","url":"https://clinicaltrials.gov/study/NCT01566721","created_at":"2021-01-18T06:38:34.789Z","updated_at":"2024-07-02T16:36:31.193Z","phase":"Phase 3","brief_title":"A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer","source_id_and_acronym":"NCT01566721 - SafeHER","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin Hylecta (trastuzumab/hyaluronidase-oysk)"],"overall_status":"Completed","enrollment":" Enrollment 2577","initiation":"Initiation: 05/17/2012","start_date":" 05/17/2012","primary_txt":" Primary completion: 03/10/2015","primary_completion_date":" 03/10/2015","study_txt":" Completion: 02/19/2020","study_completion_date":" 02/19/2020","last_update_posted":"2021-04-27"},{"id":"7aff2afb-d15b-45b9-b5ec-718b5eda112c","acronym":"SCHEARLY","url":"https://clinicaltrials.gov/study/NCT01940497","created_at":"2021-01-18T08:47:06.472Z","updated_at":"2024-07-02T16:36:39.281Z","phase":"Phase 3","brief_title":"A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer","source_id_and_acronym":"NCT01940497 - SCHEARLY","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • docetaxel • doxorubicin hydrochloride • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk)"],"overall_status":"Completed","enrollment":" Enrollment 240","initiation":"Initiation: 11/15/2013","start_date":" 11/15/2013","primary_txt":" Primary completion: 04/05/2016","primary_completion_date":" 04/05/2016","study_txt":" Completion: 03/27/2018","study_completion_date":" 03/27/2018","last_update_posted":"2020-11-03"},{"id":"5fa66ba6-c441-4272-8a09-c46544f86b5b","acronym":"IMMUN-HER","url":"https://clinicaltrials.gov/study/NCT03144947","created_at":"2021-01-18T15:30:02.579Z","updated_at":"2025-02-25T13:52:19.791Z","phase":"Phase 2","brief_title":"Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Trastuzumab in HER2+ Breast Cancer Patients","source_id_and_acronym":"NCT03144947 - IMMUN-HER","lead_sponsor":"Gruppo Oncologico Italiano di Ricerca Clinica","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Perjeta (pertuzumab) • cyclophosphamide • epirubicin • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 11/29/2016","start_date":" 11/29/2016","primary_txt":" Primary completion: 03/15/2021","primary_completion_date":" 03/15/2021","study_txt":" Completion: 11/01/2021","study_completion_date":" 11/01/2021","last_update_posted":"2020-10-14"},{"id":"946b9e5b-23b0-4073-a891-176ff3021d9c","acronym":"PREDIX HER2","url":"https://clinicaltrials.gov/study/NCT02568839","created_at":"2021-01-17T18:00:48.029Z","updated_at":"2025-02-25T14:00:46.818Z","phase":"Phase 2/3","brief_title":"Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer","source_id_and_acronym":"NCT02568839 - PREDIX HER2","lead_sponsor":"Thomas Hatschek","biomarkers":" HER-2 • PGR","pipe":"","alterations":" ","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • docetaxel • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • cyclophosphamide • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 202","initiation":"Initiation: 11/01/2014","start_date":" 11/01/2014","primary_txt":" Primary completion: 02/01/2019","primary_completion_date":" 02/01/2019","study_txt":" Completion: 02/01/2029","study_completion_date":" 02/01/2029","last_update_posted":"2020-08-13"},{"id":"f0f8443c-3688-4e61-9c0a-fa843b2be46e","acronym":"HerSCin","url":"https://clinicaltrials.gov/study/NCT01959386","created_at":"2021-01-18T08:54:05.378Z","updated_at":"2024-07-02T16:36:49.339Z","phase":"","brief_title":"A Study of Trastuzumab Subcutaneous in Participants With Human Epidermal Growth Factor Receptor-2 (HER2) Positive Early Breast Cancer","source_id_and_acronym":"NCT01959386 - HerSCin","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin Hylecta (trastuzumab/hyaluronidase-oysk)"],"overall_status":"Completed","enrollment":" Enrollment 1006","initiation":"Initiation: 11/07/2013","start_date":" 11/07/2013","primary_txt":" Primary completion: 01/31/2019","primary_completion_date":" 01/31/2019","study_txt":" Completion: 01/31/2019","study_completion_date":" 01/31/2019","last_update_posted":"2020-03-03"},{"id":"7dab8764-0212-4008-a023-0dae476e1864","acronym":"","url":"https://clinicaltrials.gov/study/NCT01926886","created_at":"2021-01-18T08:42:06.161Z","updated_at":"2024-07-02T16:36:55.607Z","phase":"Phase 3","brief_title":"A Study of Subcutaneous At Home Administration of Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2-positive (HER2+) Early Breast Cancer (eBC)","source_id_and_acronym":"NCT01926886","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin Hylecta (trastuzumab/hyaluronidase-oysk)"],"overall_status":"Completed","enrollment":" Enrollment 102","initiation":"Initiation: 11/19/2013","start_date":" 11/19/2013","primary_txt":" Primary completion: 09/04/2015","primary_completion_date":" 09/04/2015","study_txt":" Completion: 07/19/2017","study_completion_date":" 07/19/2017","last_update_posted":"2019-09-18"},{"id":"620c3ce8-9d71-49da-b105-06e475b20239","acronym":"","url":"https://clinicaltrials.gov/study/NCT02402712","created_at":"2021-01-18T11:28:09.788Z","updated_at":"2025-02-25T14:00:38.485Z","phase":"Phase 3","brief_title":"Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer","source_id_and_acronym":"NCT02402712","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Perjeta (pertuzumab) • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk)"],"overall_status":"Completed","enrollment":" Enrollment 418","initiation":"Initiation: 05/06/2015","start_date":" 05/06/2015","primary_txt":" Primary completion: 02/22/2019","primary_completion_date":" 02/22/2019","study_txt":" Completion: 02/22/2019","study_completion_date":" 02/22/2019","last_update_posted":"2019-09-06"},{"id":"99a99bc4-2948-45f6-8544-1221477ddc98","acronym":"ESCAPE","url":"https://clinicaltrials.gov/study/NCT02194166","created_at":"2021-01-18T10:14:53.081Z","updated_at":"2024-07-02T16:36:58.982Z","phase":"Phase 3","brief_title":"A Study to Investigate the Tolerability of Subcutaneous (SC) Trastuzumab Administration in Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Early Breast Cancer (eBC) Using Either a Single-Use Injection Device or Manual Administration","source_id_and_acronym":"NCT02194166 - ESCAPE","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • docetaxel • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk)"],"overall_status":"Completed","enrollment":" Enrollment 90","initiation":"Initiation: 07/18/2014","start_date":" 07/18/2014","primary_txt":" Primary completion: 07/12/2018","primary_completion_date":" 07/12/2018","study_txt":" Completion: 07/12/2018","study_completion_date":" 07/12/2018","last_update_posted":"2019-06-10"},{"id":"a32e86fd-b975-43f2-a5e5-0246b75ed183","acronym":"ARETTA","url":"https://clinicaltrials.gov/study/NCT03058939","created_at":"2021-01-18T15:04:01.335Z","updated_at":"2025-02-25T13:52:15.745Z","phase":"Phase 2","brief_title":"Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer","source_id_and_acronym":"NCT03058939 - ARETTA","lead_sponsor":"University of Chicago","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • tamoxifen • Perjeta (pertuzumab) • letrozole • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/01/2018","start_date":" 11/01/2018","primary_txt":" Primary completion: 04/01/2019","primary_completion_date":" 04/01/2019","study_txt":" Completion: 06/01/2019","study_completion_date":" 06/01/2019","last_update_posted":"2019-04-22"},{"id":"a1f8204c-ddce-4bc4-b002-25fc5f144a79","acronym":"NeoPATH","url":"https://clinicaltrials.gov/study/NCT03881878","created_at":"2021-01-18T19:08:08.212Z","updated_at":"2025-02-25T13:52:49.735Z","phase":"Phase 1/2","brief_title":"TAHP for Patients With HER2-positive Early Breast Cancer and Subsequent AHP Adjuvant tHerapy After Surgery","source_id_and_acronym":"NCT03881878 - NeoPATH","lead_sponsor":"Samsung Medical Center","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • docetaxel • Perjeta (pertuzumab) • doxorubicin hydrochloride • cyclophosphamide • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 67","initiation":"Initiation: 05/27/2019","start_date":" 05/27/2019","primary_txt":" Primary completion: 10/31/2022","primary_completion_date":" 10/31/2022","study_txt":" Completion: 10/31/2022","study_completion_date":" 10/31/2022","last_update_posted":"2019-03-21"},{"id":"d2ad5895-14a5-4652-9844-461f83fbe151","acronym":"","url":"https://clinicaltrials.gov/study/NCT00950300","created_at":"2021-01-17T17:32:06.173Z","updated_at":"2024-07-02T16:37:14.640Z","phase":"Phase 3","brief_title":"A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer","source_id_and_acronym":"NCT00950300","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • 5-fluorouracil • cyclophosphamide • epirubicin • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 596","initiation":"Initiation: 10/16/2009","start_date":" 10/16/2009","primary_txt":" Primary completion: 07/12/2011","primary_completion_date":" 07/12/2011","study_txt":" Completion: 01/24/2017","study_completion_date":" 01/24/2017","last_update_posted":"2018-01-23"},{"id":"c1ef8832-9fed-4109-93ac-4e3e2aa2b702","acronym":"","url":"https://clinicaltrials.gov/study/NCT02286362","created_at":"2021-01-18T10:46:28.278Z","updated_at":"2024-07-02T16:37:17.483Z","phase":"","brief_title":"An Observational Study of the Safety of Herceptin Given Subcutaneously in Patients With Early HER2-positive Breast Cancer","source_id_and_acronym":"NCT02286362","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk)"],"overall_status":"Completed","enrollment":" Enrollment 510","initiation":"Initiation: 01/14/2015","start_date":" 01/14/2015","primary_txt":" Primary completion: 11/10/2016","primary_completion_date":" 11/10/2016","study_txt":" Completion: 11/10/2016","study_completion_date":" 11/10/2016","last_update_posted":"2017-09-27"},{"id":"fbc6a08f-26a0-42f6-a188-4c1a8d373318","acronym":"","url":"https://clinicaltrials.gov/study/NCT01401166","created_at":"2021-01-18T05:45:24.086Z","updated_at":"2024-07-02T16:37:24.731Z","phase":"Phase 2","brief_title":"Participant Preference of Subcutaneous (SC) Versus Intravenous (IV) Herceptin (Trastuzumab) in Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer","source_id_and_acronym":"NCT01401166","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk)"],"overall_status":"Completed","enrollment":" Enrollment 488","initiation":"Initiation: 10/01/2011","start_date":" 10/01/2011","primary_txt":" Primary completion: 05/01/2013","primary_completion_date":" 05/01/2013","study_txt":" Completion: 12/01/2015","study_completion_date":" 12/01/2015","last_update_posted":"2017-03-06"}]